|
|
Volumn 2, Issue 4, 2011, Pages 183-184
|
|
ACS chemical neuroscience molecule spotlight on Qnexa
a,b
|
|
Author keywords
obesity; phentermine; Qnexa; topiramate; weight loss
|
|
Indexed keywords
AMPA RECEPTOR;
ANTIOBESITY AGENT;
CHLORIDE CHANNEL;
PHENTERMINE;
QNEXA;
TOPIRAMATE;
UNCLASSIFIED DRUG;
VI 0521;
ANXIETY DISORDER;
ATTENTION;
CARDIOVASCULAR DISEASE;
COGNITIVE DEFECT;
CONFUSION;
DEPRESSION;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG MEGADOSE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HYPERTENSION;
LANGUAGE DISABILITY;
LOW DRUG DOSE;
MEMORY DISORDER;
METABOLIC ACIDOSIS;
MIGRAINE;
NEOPLASM;
NEUROSCIENCE;
OBESITY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RECOMMENDED DRUG DOSE;
REVIEW;
SEIZURE;
SIDE EFFECT;
SLEEP DISORDER;
SPEECH DISORDER;
STROKE;
TERATOGENICITY;
WEIGHT REDUCTION;
ANTI-OBESITY AGENTS;
APPETITE DEPRESSANTS;
CLINICAL TRIALS, PHASE III AS TOPIC;
COMORBIDITY;
DOUBLE-BLIND METHOD;
DRUG APPROVAL;
DRUG COMBINATIONS;
FRUCTOSE;
HUMANS;
OBESITY;
OVERWEIGHT;
PHENTERMINE;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
WEIGHT LOSS;
|
|
EID: 79955099696
PISSN: None
EISSN: 19487193
Source Type: Journal
DOI: 10.1021/cn200023v Document Type: Review |
|
Times cited : (5)
|
|
References (8)
|
